Clinical trials: Spondyloarthrosis
Spondylitis, Ankylosing
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
- Trial name
- MEASURE 3 (NCT02008916)
- Testing
- Secukinumab
- Where
- 57 sites in United States, Belgium and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)
This two-part study was to evaluate the effect of golimumab (SCH 900259, MK-8259) in participants with active axial spondyloarthritis (axial SpA).
- Trial name
- GO-AHEAD (NCT01453725)
- Testing
- Golimumab
- Volunteers
- 198 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriatic Arthritis
Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis
This is an epidemiological non-interventional study assessing the prevalence of anxiety and/or depression disorders in patients suffering from Psoriatic Arthritis (PsA) in Spain.
- Trial name
- NCT00884468
- Where
- Spain
- Volunteers
- 384 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Ankylosing Spondylitis
Defining Remission With Etanercept in AS in Real Life Clinical Practice
Determine which remission criterion at Month 6 predicts remission at Month 12 the best.
- Trial name
- REACH AS (NCT02202850)
- Testing
- etanercept
- Where
- 29 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Pfizer
Psoriatic Arthritis
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.
- Trial name
- NCT01111240
- Where
- 509 sites in Germany
- Volunteers
- 4,635 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had…
- Trial name
- NCT04908189
- Testing
- Deucravacitinib, Apremilast
- Where
- 138 sites in United States, Argentina and 16 more
- Volunteers
- 729 people
- Sponsor
- Bristol-Myers Squibb
Spondylitis, Ankylosing, Arthritis, Psoriatic
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
- Trial name
- NCT03733925
- Testing
- Golimumab
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Private Limited
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Psoriatic Arthritis
Psoriatic Arthritis Study of Izokibep
Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.
- Trial name
- NCT05623345
- Testing
- Izokibep
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 351 people
- Sponsor
- ACELYRIN Inc.
Ankylosing Spondylitis
Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis
Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as treatment of moderate to severe ankylosing spondylitis (AS).
- Trial name
- NCT00809159
- Testing
- AIN457
- Where
- 20 sites in United States, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
This is a multicenter, prospective, non-interventional, observational single arm study. 100 patients will be recruited in the Netherlands over a one year period.
- Trial name
- REWARD (NCT02875184)
- Where
- 21 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Amgen
Psoriatic Arthritis
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis.
- Trial name
- PERIS (NCT06764693)
- Where
- 132 sites in Argentina, Austria and 13 more
- Volunteers
- 1,200 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish…
- Trial name
- DANBIO (NCT05421442)
- Where
- United States
- Volunteers
- 38,396 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Psoriatic
Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions
A total of approximately 500 patients with active psoriatic arthritis in an estimated 80 to 100 trial centers are to be enrolled. Selection of centers will be made by the sponsor's medical section.
- Trial name
- LAPIS-PsA (NCT03106051)
- Where
- 2 sites in Germany
- Volunteers
- 526 people
- Sponsor
- Amgen
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AK111 in subjects with active ankylosing spondylitis.
- Trial name
- NCT05467995
- Testing
- AK111
- Where
- 15 sites in China
- Volunteers
- 125 people
- Sponsor
- Akeso
Ankylosing Spondylitis, Coxitis
Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab
Rationale. Coxitis in AS is inflammation of hip(s) affecting significant number of patients. It is associated with worse function and more expressed axial disease requiring hip replacement at end-stage.
- Trial name
- GO-COX (NCT03557853)
- Testing
- Golimumab Injection
- Where
- 6 sites in Russia
- Volunteers
- 39 people
- Sponsor
- MSD Pharmaceuticals LLC
Rheumatoid Arthritis, Ankylosing Spondylitis
99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
This was a monocentric, open label, Phase I-IIa study. Eligible patients who signed the ICF received two single intravenous (IV) bolus of the imaging agent 99mTc-rhAnnexin V-128.
- Trial name
- NCT02328027
- Testing
- 99mTc-rhAnnexin V-128
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Advanced Accelerator Applications
Psoriatic Arthritis
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.
- Trial name
- NCT02267642
- Testing
- AbGn-168H
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Ankylosing Spondylitis
Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain
The purpose of this study was to evaluate efficacy and safety of etanercept 100 mg (50 mg twice a week) compared with 50 mg once a week in adult subjects with ankylosing spondylitis (AS) and previous failure to usual practice…
- Trial name
- Loadet (NCT00873730)
- Testing
- etanercept
- Volunteers
- 108 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Ankylosing Spondylitis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy
The primary objective of this study is to evaluate the effect of filgotinib versus placebo on signs and symptoms of active ankylosing spondylitis (AS), evaluated by Assessment of SpondyloArthritis international Society 40%…
- Trial name
- SEALION2-NAÏVE (NCT04483700)
- Testing
- Filgotinib
- Sponsor
- Gilead Sciences